ILMN

Business Context and Reporting Period

Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically its proprietary BeadArray technology. The company has no commercially available products as of the reporting date and generates revenue primarily from government grants and strategic partnerships. The company completed its Initial Public Offering (IPO) on July 28, 2000.

Key Financial Metrics

Note: Revenue is derived almost entirely from government grants. The company has an accumulated deficit of approximately $20.7 million.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $21.2 million (Dec 31, 1999) to $121.6 million (Sep 30, 2000), driven by net proceeds of approximately $101.4 million from the IPO and over-allotment exercise.
• Revenue Growth: Revenue for the nine months ended Sep 30, 2000 ($0.8 million) was significantly higher than the prior year period ($0.3 million), attributed to new government grants.
• Expense Expansion:
  • R&D Expenses: Increased to $9.7 million for the nine months ended Sep 30, 2000, from $2.7 million in the prior year. This includes a $1.6 million charge for the acquisition of in-process technologies.
  • Non-Cash Compensation: Amortization of deferred compensation rose to $4.8 million for the nine-month period, compared to $0.4 million in the prior year, due to increased staffing and higher stock valuations.
• Interest Income: Net interest income increased to $2.5 million for the nine-month period (from $0.3 million) due to higher cash and investment balances.

Outlook, Risks, and Management Commentary

• Commercialization Timeline: Management expects to commercialize its first products in 2001 in partnership with PE Biosystems. No revenue from product sales has been generated to date.
• Liquidity Position: Management believes current cash, investments, and funding from strategic alliances are sufficient to fund operations for at least the next 24 months.
• Capital Requirements: The company expects to incur substantial operating losses in the future. Additional funding may be required sooner than anticipated, which could be dilutive to existing shareholders.
• Key Risks:
  • Technology Risk: Products are based on new, unproven technology; commercial success is not guaranteed.
  • Manufacturing: The company has limited manufacturing experience and relies on third-party suppliers for critical components (e.g., fiber optic bundles).
  • Partnership Dependence: Success depends heavily on the PE Biosystems partnership and other collaborations for product development and marketing.
  • Market Acceptance: Target markets (SNP genotyping, gene expression profiling) are emerging and may not develop as anticipated.
• Unusual Items: A $1.6 million charge was recorded in March 2000 for the purchase of in-process technologies that had not yet achieved technological feasibility.

Investor Verification Checklist

• Product Launch: Verify the status of the partnership with PE Biosystems and the timeline for the 2001 product commercialization.
• Burn Rate: Monitor quarterly operating cash flow usage against the $121.6 million cash balance to validate the 24-month runway claim.
• Revenue Mix: Confirm the sustainability of government grant revenue versus the potential for commercial product sales.
• Real Estate Commitment: Review the $6.2 million note receivable and the option to purchase the new 97,000 sq. ft. facility, including the $2.3 million additional cash payment required upon exercise.
• Stock Compensation: Assess the impact of future stock option grants and the amortization of deferred compensation on future net losses.